Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

BMC Neurology

Volumn 16, Issue 1, 2016, Pages

  Gold, Ralf ^a   Radue, Ernst Wilhelm ^b   Giovannoni, Gavin ^c   Selmaj, Krzysztof ^d   Havrdova, Eva ^e   Stefoski, Dusan ^f   Sprenger, Till ^b,g   Montalban, Xavier ^h   Cohan, Stanley ⁱ   Umans, Kimberly ^j   Greenberg, Steven J ^k   Ozen, Gulden ^j   Elkins, Jacob ^j  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e CHARLES UNIVERSITY   (Czech Republic)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g DKD Helios Klinik Wiesbaden   (Germany)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ Providence Multiple Sclerosis Center   (United States)

^j BIOGEN   (United States)

^k ABBVIE INC   (United States)

more..

Author keywords

Daclizumab; Efficacy; Relapsing remitting multiple sclerosis; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DACLIZUMAB; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ADULT; ANUS CANCER; ARTICLE; AUTOIMMUNE HEPATITIS; BACKACHE; BRAIN SIZE; BRONCHITIS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ERYTHRODERMIC PSORIASIS; FEMALE; FRACTURE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HEPATOBILIARY DISEASE; HERPES SIMPLEX; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVERTEBRAL DISK DISEASE; LIVER DISEASE; LUNG CARCINOMA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MONONUCLEOSIS; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHARYNGITIS; PHOTODERMATOSIS; PNEUMONIA; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; SKIN ALLERGY; SKIN DISEASE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; BRAIN; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECTS; DRUG ERUPTIONS; FOLLOW UP; LONGITUDINAL STUDY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; SAFETY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL, HUMANIZED; ASPARTATE AMINOTRANSFERASES; BRAIN; COHORT STUDIES; COLITIS, ULCERATIVE; DRUG ERUPTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; INTENTION TO TREAT ANALYSIS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NASOPHARYNGITIS; PNEUMONIA; RECURRENCE; RESPIRATORY TRACT INFECTIONS; SAFETY; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84979263815     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-016-0635-y     Document Type: Article

References (9)

1. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today. 1993;14:264-70.
2. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9:394-404.
3. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167-75.
4. Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13:472-81.
5. World Health Organization. Global Tuberculosis Report 2013 [Ukraine country profile]. http://www.who.int/tb/country/data/profiles/en/. Accessed 12 October 2015.
6. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418-28.
7. Herndon RM, Rudick RA, Munschauer FE III, Mass MK, Salazar AM, Coats ME, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex® [superscript] treatment in patients with multiple sclerosis. Mult Scler. 2005;11:409-19.
8. Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: results of open-label extensions of two Phase 3 clinical trials. Mult Scler. 2015;21:1322-31.
9. Radue E-W, Giovannoni G, Gold R, Selmaj K, Havrdova E, Stefoski D, et al. Long-term efficacy of daclizumab HYP in relapsing-remitting multiple sclerosis: 3 year results from the SELECTED extension study. Neurology. 2015;84:P7.226.